Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14-Lysine modified PspA

Vaccine

Volumn 29, Issue 47, 2011, Pages 8689-8695

  Santamaria, Raquel ^a   Goulart, Cibelly ^a   Perciani, Catia T ^a   Barazzone, Giovana C ^a   Carvalho, Rimenys ^a   Gonçalves, Viviane M ^a   Leite, Luciana C C ^a   Tanizaki, Martha M ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

Capsular polysaccharide serotype 14; Conjugate vaccine; PspA; Streptococcus pneumoniae

Indexed keywords

1 [3 (DIMETHYLAMINE)PROPYL] 3 ETHYLCARBODIIMIDE; 4 (4,6 DIMETHOXY 1,3,5 TRIAZIN 2 YL) 4 METHYLMORPHOLINIUM CHLORIDE; CYANAMIDE; DRUG CARRIER; FORMALDEHYDE; IMMUNOGLOBULIN G1; MORPHOLINE DERIVATIVE; OUTER SURFACE PROTEIN A; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AMINATION; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; COMPLEMENT SYSTEM PROTEINS; FEMALE; IMMUNOGLOBULIN G; LYSINE; MICE; MICE, INBRED BALB C; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; VACCINATION; VACCINES, CONJUGATE;

EID: 82455205671     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.109     Document Type: Article

References (38)

1. Bingen E., Levy C., Varon E., De la Rocque F., Boucherat M., d'Athis P., et al. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur J Clin Microbiol Infect Dis 2008, 27:191-199.
2. Grijalva C.G., Poehling K.A., Nuorti J.P., Zhu Y., Martin S.W., Edwards K.M., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006, 118:865-873.
3. Whitney C.G., Farley M.M., Hadler J., Hadler J., Harrison L.H., Bennett N.M., et al. Decline in invasive pneumococcal disease after the introduction of protein polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
4. Ramani R.R., Hall W.N., Boulton M., Johnson D.R., Zhu B.P. Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study. Am J Public Health 2004, 94:958-959.
5. Dagan R., Poolman J., Siegrist C.A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010, 28:5513-5523.
6. Knuf M., Kowalzik F., Kieningerb D. Camparative effects of carrier proteins on vaccine-oinduced immune response. Vaccine 2011, 29:4881-4890.
7. Muñoz-Almagro C., Jordan I., Gene A., Latorre A., Garcia-Garcia J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Vaccine 2010, 28:5167-5173.
8. Aguiar S.I., Brito M.J., Gonçalo-Marques J., Melo-Cristino J., Ramirez M. Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Clin Infect Dis 2008, 46:174-182.
9. Beall B., Gherardi G., Facklam R.R., Hollingshead S.K. Pneumococcal PspA sequence types of prevalent multiresistant pneumococcal strains in the United States and of internationally disseminated clones. J Clin Microbiol 2000, 38:3663-3669.
10. Kerr A.R., Paterson G.K., McCluskey J., Iannelli F., Oggioni M.R., Pozzi G., et al. The contribution of PspC to pneumococcal virulence varies between strains and is accomplished by both complement evasion and complement-independent mechanisms. Infect Immun 2006, 74:5319-5324.
11. Molloy S. Pneumolysin: stimulating protection. Nat Rev Microbiol 2011, 9:4.
12. Giefinq C., Jelencsics K.E., Gelbmann D., Senn B.M., Nagy E. The pneumococcal eukaryotic type serine/threonine protein kinase StkP co-localizes with the cell division apparatus and interacts with FtsZ in vitro. Microbiology 2010, 156:1697-1707.
13. Castañeda E., Agudelo C.I., Regueira M., Corso A., Brandileone M.C., Brandão A.P., et al. Laboratory-based surveillance of Streptococcus pneumoniae disease in children in 10 Latin America countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J 2009, 28:264-270.
14. Andrade A.L., Franco C.M., Lamaro-Cardoso J., André M.C., Oliveira L.L., Kipnis A., et al. Non-typable Streptococcus pneumoniae carriage isolates genetically similar to invasive and carriage isolates expressing capsular type 14 in Brazilian infants. J Infect 2010, 61:314-322.
15. Ren B., Szalai A.J., Hollingshead S.K., Briles D.E. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 2004, 72:114-122.
16. Silva M., Cabrera-Crespo J., Sbrogio-Almeida M.E., Miyagi E.M., Ho P.L., LeiteLCC, et al. Optimizing expression of Streptococcus pneumoniae surface protein A. PspA: serocross reactivity within families of antisera induced against clade 1 and 3. Mol Biotechnol 2007, 37:146-154.
17. Barazzone C.B., Carvalho R., Kraschowetz S., Horta A.C., Sargo C.R., Silva A.J., et al. Production and purification of recombinant fragment of pneumococcal surface protein A (PspA) in Escherichia coli. Procedia in vaccinology 4th vaccine and ISV global annual congress 2010.
18. Cuesta G., Suarez N., Bessio M.I., Ferreira F., Massaldi H. Quantitative determination of pneumococcal capsular polysaccharide serotype 14 using a modification of phenol-sulfuric acid method. J Microb Methods 2003, 52:69-73.
19. Tyllianakis P.E., Kakabacos S.E., EvangelatosGP, Ithakissios D.S. Direct colorimetric determination of solid-supported functional groups and ligands using bicinchoninic acid. Anal Biochem 1994, 219:335-340.
20. Qi X.Y., Keyhani N.O., Lee Y.C. Spectrophotometric determination of hydrazine, hydrazides, and their mixtures with trinitrobenzenesulfonic acid. Anal Biochem 1988, 175:139-144.
21. Perciani C.T., Peixoto P.S., Dias W.O., Kubrusly F.S., Tanizaki M.M., Perciani C.T., et al. Improved method to calculate the antibody avidity index. Clin Lab Anal 2007, 21:201-206.
22. Goulart C., Darrieux M., Rodriguez D., Pimenta F.C., Brandileone M.C., de Andrade A.L., et al. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine 2011, 29:1634-1642.
23. Csordas F.C., Perciani C.T., Darrieux M., Gonçalves V.M., Cabrera-Crespo J., Takagi M., et al. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide. Vaccine 2008, 26:2925-2929.
24. McLay J., Leonard E., Petersen S., Shapiro D., Greespan N.S., Schreiber J.R. γ3 Gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. J Immunol 2002, 168:3437-3443.
25. Shaper M., Hollingshead S.K., Benjamin W.H., Briles D.E. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin. Infect Immun 2004, 72:5031-5040.
26. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006, 32:139-153.
27. Cao J., Chen D., Xu W., Chen T., Xu S., Luo J., et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 2007, 25:4996-5005.
28. Oliveira M.L., Miyaji E.N., Ferreira D.M., Moreno A.T., Ferreira P.C., Lima F.A., et al. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One 2010, 5:e10863.
29. + T cell help. J Immunol 2004, 172:532-539.
30. Hollingshead S.K., Becker R., Briles D.E. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000, 68:5889-5900.
31. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenza type b polysaccharides protein conjugates. J Exp Med 1980, 152:361-376.
32. Kunishima M., Kawachi C., Hioki K., Terao K., Tani S. Formation of carboxamides by direct condensation of carboxylic acids and amines in alcohols using a new alcohol- and watersoluble condensing agent: DMT-MM. Tetrahedron 2001, 57:1551-1558.
33. Schlottmann S.A., Jain N., Chirmule N., Esser M.T. A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheres. J Immunol Methods 2006, 309:75-85.
34. Gilles M.A., Hudson A.Q., Borders C.L. Stability of water-soluble carbodiimides in aqueous solution. Anal Biochem 1990, 184:244-248.
35. Nakajima N., Ikada Y. Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media. Bioconjug Chem 1995, 6:123-130.
36. Kaboj K.K., Kirchner H.L., Kimmel R., Greespan N.S., Schreiber J.R. Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. J Infect Dis 2003, 187:1629-1638.
37. Leonard E.G., Canaday D.H., HardingCV SchreiberJ.R. Antigen processing of the heptavalent pneumococcal conjugate vaccine carrier protein CRM(197) differs depending on the serotype of the attached polysaccharide. Infect Immun 2003, 71:4186-4189.
38. Brown E.J., Hosea S.W., Frank M.M. The role of antibody and complement in thereticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis 1983, S797-S805.